Clinical Trial Update: Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CD19 UCAR T Cells for efficacy and safety in patients with refractory systemic lupus erythematosus; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19 UCAR T Cells

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING